<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">32357946</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>13</Day></DateCompleted><DateRevised><Year>2020</Year><Month>07</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1477-7525</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>May</Month><Day>01</Day></PubDate></JournalIssue><Title>Health and quality of life outcomes</Title><ISOAbbreviation>Health Qual Life Outcomes</ISOAbbreviation></Journal><ArticleTitle>Modelling disease course in amyotrophic lateral Sclerosis: pseudo-longitudinal insights from cross-sectional health-related quality of life data.</ArticleTitle><Pagination><StartPage>117</StartPage><MedlinePgn>117</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">117</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12955-020-01372-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Amyotrophic Lateral Sclerosis (ALS) is a rapidly progressive neurodegenerative disorder with limited robust disease-modifying therapies presently available. While several treatments are aimed at improving health-related quality of life (HRQoL), longitudinal data on how QoL changes across the disease course are rare.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To explore longitudinal changes in emotional well-being and HRQoL in ALS.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Of the 161 subjects initially recruited, 39 received 2 subsequent follow-up assessments at 6 and 12&#x2009;months after baseline. The ALS Functional Rating Scale-Revised (ALSFRS-R) was used to assess physical impairment. HRQoL was assessed using the ALS Assessment Questionnaire (ALSAQ-40). The D50 disease progression model was applied to explore longitudinal changes in HRQoL.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients were primarily in the early semi-stable and early progressive model-derived disease phases. Non-linear correlation analyses showed that the ALSAQ-40 summary index and emotional well-being subdomain behaved differently across disease phases, indicating that the response shift occurs early in disease. Both the ALSFRS-R and ALSAQ-40 significantly declined at 6- and 12-monthly follow-ups.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">ALSAQ-40 summary index and emotional well-being change comparably over both actual time and model-derived phases, indicating that the D50 model enables pseudo-longitudinal interpretations of cross-sectional data in ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Prell</LastName><ForeName>Tino</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Hans Berger Department of Neurology, Jena University Hospital, Am Klinikum 1, 07747, Jena, Germany. Tino.prell@med.uni-jena.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Healthy Ageing, Jena University Hospital, Jena, Germany. Tino.prell@med.uni-jena.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaur</LastName><ForeName>Nayana</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-7854-6247</Identifier><AffiliationInfo><Affiliation>Hans Berger Department of Neurology, Jena University Hospital, Am Klinikum 1, 07747, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steinbach</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Hans Berger Department of Neurology, Jena University Hospital, Am Klinikum 1, 07747, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Witte</LastName><ForeName>Otto W</ForeName><Initials>OW</Initials><AffiliationInfo><Affiliation>Hans Berger Department of Neurology, Jena University Hospital, Am Klinikum 1, 07747, Jena, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Healthy Ageing, Jena University Hospital, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grosskreutz</LastName><ForeName>Julian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hans Berger Department of Neurology, Jena University Hospital, Am Klinikum 1, 07747, Jena, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Healthy Ageing, Jena University Hospital, Jena, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Health Qual Life Outcomes</MedlineTA><NlmUniqueID>101153626</NlmUniqueID><ISSNLinking>1477-7525</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004185" MajorTopicYN="N">Disability Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000076604" MajorTopicYN="N">Physical Functional Performance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Disease aggressiveness</Keyword><Keyword MajorTopicYN="N">Health-related quality of life</Keyword><Keyword MajorTopicYN="N">Longitudinal modelling</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32357946</ArticleId><ArticleId IdType="pmc">PMC7195704</ArticleId><ArticleId IdType="doi">10.1186/s12955-020-01372-6</ArticleId><ArticleId IdType="pii">10.1186/s12955-020-01372-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardiman O, Sclerosis AL. Nature reviews Disease Primers. 2017:5(3).</Citation></Reference><Reference><Citation>Bock M, et al. Progression and effect of cognitive-behavioral changes in patients with amyotrophic lateral sclerosis. Neurol Clin Pract. 2017;7(6):488&#x2013;498. doi: 10.1212/CPJ.0000000000000397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/CPJ.0000000000000397</ArticleId><ArticleId IdType="pmc">PMC5800712</ArticleId><ArticleId IdType="pubmed">29431172</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmons Z. Patient-perceived outcomes and quality of life in ALS. Neurotherapeutics. 2015;12(2):394&#x2013;402. doi: 10.1007/s13311-014-0322-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-014-0322-x</ArticleId><ArticleId IdType="pmc">PMC4404446</ArticleId><ArticleId IdType="pubmed">25502407</ArticleId></ArticleIdList></Reference><Reference><Citation>Poesen K, et al. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology. 2017;88(24):2302&#x2013;2309. doi: 10.1212/WNL.0000000000004029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004029</ArticleId><ArticleId IdType="pubmed">28500227</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS study group (phase III) J Neurol Sci. 1999;169(1&#x2013;2):13&#x2013;21. doi: 10.1016/S0022-510X(99)00210-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkinson C, et al. Development and validation of a short measure of health status for individuals with amyotrophic lateral sclerosis/motor neurone disease: the ALSAQ-40. J Neurol. 1999;246(Suppl 3):III16&#x2013;III21. doi: 10.1007/BF03161085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF03161085</ArticleId><ArticleId IdType="pubmed">10631656</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakore NJ, et al. Trajectories of impairment in amyotrophic lateral sclerosis: insights from the pooled resource open-access ALS clinical trials cohort. Muscle Nerve. 2017.</Citation><ArticleIdList><ArticleId IdType="pubmed">29244213</ArticleId></ArticleIdList></Reference><Reference><Citation>Perner C, et al. Plasma VCAM1 levels correlate with disease severity in Parkinson's disease. J Neuroinflammation. 2019;16(1):94. doi: 10.1186/s12974-019-1482-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-019-1482-8</ArticleId><ArticleId IdType="pmc">PMC6507178</ArticleId><ArticleId IdType="pubmed">31068198</ArticleId></ArticleIdList></Reference><Reference><Citation>Prell T, et al. Reaction to endoplasmic reticulum stress via ATF6 in amyotrophic lateral Sclerosis deteriorates with aging. Front Aging Neurosci. 2019;11:5. doi: 10.3389/fnagi.2019.00005.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2019.00005</ArticleId><ArticleId IdType="pmc">PMC6355670</ArticleId><ArticleId IdType="pubmed">30740050</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinbach R, et al. Applying the D50 disease progression model to gray and white matter pathology in amyotrophic lateral sclerosis. Neuroimage Clin. 2020;25:102094. doi: 10.1016/j.nicl.2019.102094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2019.102094</ArticleId><ArticleId IdType="pmc">PMC6940701</ArticleId><ArticleId IdType="pubmed">31896467</ArticleId></ArticleIdList></Reference><Reference><Citation>Shamshiri H, et al. Trends of quality of life changes in amyotrophic lateral sclerosis patients. J Neurol Sci. 2016;368:35&#x2013;40. doi: 10.1016/j.jns.2016.06.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2016.06.056</ArticleId><ArticleId IdType="pubmed">27538598</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdulla S, et al. The impact of physical impairment on emotional well-being in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(5&#x2013;6):392&#x2013;397. doi: 10.3109/21678421.2014.932380.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.932380</ArticleId><ArticleId IdType="pubmed">25008979</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Campo Y, et al. Observational study of patients in Spain with amyotrophic lateral sclerosis: correlations between clinical status, quality of life, and dignity. BMC Palliat Care. 2017;16(1):75. doi: 10.1186/s12904-017-0260-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12904-017-0260-6</ArticleId><ArticleId IdType="pmc">PMC5735656</ArticleId><ArticleId IdType="pubmed">29258495</ArticleId></ArticleIdList></Reference><Reference><Citation>Robbins RA, et al. Quality of life in ALS is maintained as physical function declines. Neurology. 2001;56(4):442&#x2013;4. doi: 10.1212/WNL.56.4.442.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.56.4.442</ArticleId><ArticleId IdType="pubmed">11222784</ArticleId></ArticleIdList></Reference><Reference><Citation>Roach AR, et al. The dynamics of quality of life in ALS patients and caregivers. Ann Behav Med. 2009;37(2):197&#x2013;206. doi: 10.1007/s12160-009-9092-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12160-009-9092-9</ArticleId><ArticleId IdType="pubmed">19350337</ArticleId></ArticleIdList></Reference><Reference><Citation>Cupp J, et al. Psychological health in patients with ALS is maintained as physical function declines. Amyotroph Lateral Scler. 2011;12(4):290&#x2013;296. doi: 10.3109/17482968.2011.554555.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2011.554555</ArticleId><ArticleId IdType="pubmed">21294667</ArticleId></ArticleIdList></Reference><Reference><Citation>Sajobi TT, et al. Scoping review of response shift methods: current reporting practices and recommendations. Qual Life Res. 2018;27(5):1133&#x2013;1146. doi: 10.1007/s11136-017-1751-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11136-017-1751-x</ArticleId><ArticleId IdType="pubmed">29210014</ArticleId></ArticleIdList></Reference><Reference><Citation>Sprangers MA, Schwartz CE. Integrating response shift into health-related quality of life research: a theoretical model. Soc Sci Med. 1999;48(11):1507&#x2013;1515. doi: 10.1016/S0277-9536(99)00045-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0277-9536(99)00045-3</ArticleId><ArticleId IdType="pubmed">10400253</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>